EA202090617A1 - Варианты антител - Google Patents
Варианты антителInfo
- Publication number
- EA202090617A1 EA202090617A1 EA202090617A EA202090617A EA202090617A1 EA 202090617 A1 EA202090617 A1 EA 202090617A1 EA 202090617 A EA202090617 A EA 202090617A EA 202090617 A EA202090617 A EA 202090617A EA 202090617 A1 EA202090617 A1 EA 202090617A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- options
- antibody
- present
- antibody options
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к антителам, которые связываются с ФНО- и демонстрируют модифицированное связывание FcRn. Антитела согласно настоящему изобретению обладают хорошими эффекторными функциями и/или фармакокинетическими свойствами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17191989.7A EP3456738A1 (en) | 2017-09-19 | 2017-09-19 | Antibody variants |
PCT/EP2018/074522 WO2019057564A1 (en) | 2017-09-19 | 2018-09-11 | ANTIBODY VARIANTS |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090617A1 true EA202090617A1 (ru) | 2020-07-27 |
Family
ID=59923275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090617A EA202090617A1 (ru) | 2017-09-19 | 2018-09-11 | Варианты антител |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP3456738A1 (ru) |
JP (2) | JP7240385B2 (ru) |
KR (1) | KR20200053514A (ru) |
CN (1) | CN111094343A (ru) |
AR (1) | AR113303A1 (ru) |
AU (1) | AU2018337495A1 (ru) |
BR (1) | BR112020005482A2 (ru) |
CA (1) | CA3075959A1 (ru) |
CL (1) | CL2020000721A1 (ru) |
CO (1) | CO2020003260A2 (ru) |
CR (2) | CR20200132A (ru) |
EA (1) | EA202090617A1 (ru) |
GE (1) | GEP20237484B (ru) |
IL (1) | IL273351A (ru) |
JO (1) | JOP20200063A1 (ru) |
MA (1) | MA50156A (ru) |
MX (1) | MX2020002989A (ru) |
PH (1) | PH12020500473A1 (ru) |
SG (1) | SG11202002220TA (ru) |
TW (1) | TW201915021A (ru) |
WO (1) | WO2019057564A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019001458A (es) | 2016-08-02 | 2019-07-04 | Visterra Inc | Polipeptidos modificados y usos de los mismos. |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2348051T3 (en) * | 2003-11-05 | 2019-03-18 | Roche Glycart Ag | CD20 antibodies with increased fc receptor binding affinity and effector function |
CA2595112A1 (en) | 2004-12-31 | 2006-07-13 | Genentech, Inc. | Polypeptides that bind br3 and uses thereof |
CA3086659A1 (en) | 2007-12-26 | 2009-07-09 | Xencor, Inc. | Fc variants with altered binding to fcrn |
CN107936117B (zh) | 2008-06-25 | 2022-12-23 | 诺华股份有限公司 | 抑制TNFα的稳定和可溶的抗体 |
WO2015158867A1 (en) | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
US11319383B2 (en) * | 2016-03-14 | 2022-05-03 | Universitetet | Oslo | Engineered immunoglobulins with altered FcRn binding |
-
2017
- 2017-09-19 EP EP17191989.7A patent/EP3456738A1/en active Pending
-
2018
- 2018-09-11 JP JP2020516456A patent/JP7240385B2/ja active Active
- 2018-09-11 JO JOP/2020/0063A patent/JOP20200063A1/ar unknown
- 2018-09-11 MX MX2020002989A patent/MX2020002989A/es unknown
- 2018-09-11 CR CR20200132A patent/CR20200132A/es unknown
- 2018-09-11 CA CA3075959A patent/CA3075959A1/en active Pending
- 2018-09-11 EA EA202090617A patent/EA202090617A1/ru unknown
- 2018-09-11 MA MA050156A patent/MA50156A/fr unknown
- 2018-09-11 SG SG11202002220TA patent/SG11202002220TA/en unknown
- 2018-09-11 EP EP18762890.4A patent/EP3684807A1/en active Pending
- 2018-09-11 CR CR20210205A patent/CR20210205A/es unknown
- 2018-09-11 GE GEAP201815316A patent/GEP20237484B/en unknown
- 2018-09-11 CN CN201880060497.2A patent/CN111094343A/zh active Pending
- 2018-09-11 BR BR112020005482-8A patent/BR112020005482A2/pt unknown
- 2018-09-11 AU AU2018337495A patent/AU2018337495A1/en active Pending
- 2018-09-11 WO PCT/EP2018/074522 patent/WO2019057564A1/en active Application Filing
- 2018-09-11 KR KR1020207009263A patent/KR20200053514A/ko not_active Application Discontinuation
- 2018-09-17 TW TW107132681A patent/TW201915021A/zh unknown
- 2018-09-19 AR ARP180102664A patent/AR113303A1/es unknown
-
2020
- 2020-03-09 PH PH12020500473A patent/PH12020500473A1/en unknown
- 2020-03-17 IL IL273351A patent/IL273351A/en unknown
- 2020-03-19 CO CONC2020/0003260A patent/CO2020003260A2/es unknown
- 2020-03-19 CL CL2020000721A patent/CL2020000721A1/es unknown
-
2022
- 2022-12-27 JP JP2022210008A patent/JP7402304B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
IL273351A (en) | 2020-05-31 |
EP3456738A1 (en) | 2019-03-20 |
SG11202002220TA (en) | 2020-04-29 |
GEP20237484B (en) | 2023-03-27 |
US20200216527A1 (en) | 2020-07-09 |
PH12020500473A1 (en) | 2021-01-25 |
JP7402304B2 (ja) | 2023-12-20 |
CR20200132A (es) | 2020-07-24 |
JP2020534307A (ja) | 2020-11-26 |
CL2020000721A1 (es) | 2020-08-07 |
BR112020005482A2 (pt) | 2020-09-29 |
CO2020003260A2 (es) | 2020-04-13 |
CN111094343A (zh) | 2020-05-01 |
AU2018337495A1 (en) | 2020-04-09 |
WO2019057564A1 (en) | 2019-03-28 |
JP7240385B2 (ja) | 2023-03-15 |
KR20200053514A (ko) | 2020-05-18 |
TW201915021A (zh) | 2019-04-16 |
AR113303A1 (es) | 2020-04-08 |
JOP20200063A1 (ar) | 2020-03-17 |
CA3075959A1 (en) | 2019-03-28 |
EP3684807A1 (en) | 2020-07-29 |
JP2023036885A (ja) | 2023-03-14 |
CR20210205A (es) | 2021-07-27 |
MA50156A (fr) | 2020-07-29 |
MX2020002989A (es) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
PH12018501778A1 (en) | Antibodies to tigit | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
EA202092847A1 (ru) | Антитела к cd3 и их применение | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
MX2019012953A (es) | Anticuerpo biespecifico contra ox40 y ctla-4. | |
EA201892417A1 (ru) | Антитела, распознающие тау | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
EA201990673A1 (ru) | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты | |
EA201892412A1 (ru) | Антитела, распознающие тау | |
EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
EA201992756A3 (ru) | Антитела против cd48 и их конъюгаты | |
EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
EA201890078A1 (ru) | Антитело | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EA201991879A1 (ru) | Варианты полипептидов и их применение | |
MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
EA202090617A1 (ru) | Варианты антител | |
CY1124244T1 (el) | Παραλλαγματα αντισωματος |